Back to Search
ASHOK PATNAIK, MD
MD
Cardiovascular Disease Physician
NPI: 1942253703IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
20694(WV)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
OTHER
Class of 2001
Research & Publications (20)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
PMID 19633048·Ann Oncol·2010
3-trial
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
PMID 19147780·Clin Cancer Res·2009
3-trial
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
PMID 19281729·Int J Clin Pharmacol Ther·2009
3-trial
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
PMID 19449006·Cancer Chemother Pharmacol·2009
3-trial
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
PMID 18795291·Cancer Chemother Pharmacol·2009
3-trial
Effects of collisions on electronic-resonance-enhanced coherent anti-Stokes Raman scattering of nitric oxide.
PMID 19508066·J Chem Phys·2009
8-other
Perturbative theory and modeling of electronic-resonance-enhanced coherent anti-Stokes Raman scattering spectroscopy of nitric oxide.
PMID 18465923·J Chem Phys·2008
8-other
Spatial distribution of orofacial cleft defect births in Harris County, Texas, and radium in the public water supplies: a persistent association?
PMID 19065472·Tex Med·2008
8-other
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
PMID 18202410·J Clin Oncol·2008
3-trial
Equilibrium structure and dynamics of (2R, 3R)-(+)-bis(decyloxy)succinic acid at the air-water interface.
PMID 18177056·Langmuir·2008
8-other
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
PMID 18824702·J Clin Oncol·2008
3-trial
Controlled parametric generation in a double-ladder system via all-resonant four-wave mixing.
PMID 18278117·Opt Lett·2008
8-other
Unilamellar composite vesicles and Y-junctions from pristine fullerene C(60).
PMID 18802505·Chem Commun (Camb)·2008
8-other
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
PMID 18927309·Clin Cancer Res·2008
3-trial
Chiral discrimination of a gemini-type surfactant with rigid spacer at the air-water interface.
PMID 17845026·J Phys Chem B·2007
8-other
A new pH and thermo-responsive chiral hydrogel for stimulated release.
PMID 17629325·J Phys Chem B·2007
8-other
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
PMID 17671985·Cancer·2007
3-trial
Novel crown ether-capped cationic gold nanoclusters in an aqueous medium and their single-electron charging features.
PMID 17918974·Langmuir·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 61 E 3RD AVE
WILLIAMSON, WV 25661 - Phone
- (304) 235-8999
Quick Facts
- NPI
- 1942253703
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 25
- Publications
- 20
Are you this provider?
Claim Your Profile